Skip to main content

Evaluating Alcohol, Tobacco, and Other Substance Use in Pregnant Women

Abstract

Use of tobacco, alcohol, and psychoactive substances during pregnancy is associated with increased risks of preterm birth. Concurrent use of these substances is also quite common and further increases the risk of adverse outcomes. Health-care providers should ask pregnant women about their exposure to tobacco, second-hand smoke, alcohol, and illicit substances (past and present) at every antenatal visit using validated screening instruments and offer brief interventions.

Pregnant women with alcohol or substance dependence should be assessed individually and offered psychosocial interventions (e.g. motivational interviewing, cognitive behavioural therapy, contingency management). Pregnant women should be advised to quit and referred to detoxification services or opioid substitution treatment (for opioid users). Pharmacological treatment for maintenance and relapse prevention is not recommended for amphetamine, cannabis, and cocaine dependence and requires individual risk-benefit analysis for alcohol dependence. Opioid maintenance therapy with methadone or buprenorphine is recommended for opiate dependence. Pregnant women who are current tobacco users or have recently quit should be offered psychosocial interventions (e.g. counselling, incentives, social support). Evidence on impact of pharmacological interventions for cessation of tobacco use is limited. Interventions to make public places and homes smoke-free are recommended. Evidence of impact of these interventions in reducing PTB especially in LMIC settings is low and further research recommended.

Keywords

  • Alcohol
  • Tobacco
  • Second-hand smoke
  • Substance use
  • Preterm birth

1 Background

Substance use disorder in pregnancy is a critical public health concern that is linked with several adverse maternal and newborn health outcomes including preterm birth (PTB), low birth weight (LBW), and small for gestational age (SGA) babies. The most widely used substances in pregnancy in high-, low-, and middle-income countries (LMICs) include tobacco, alcohol, cannabis, opiates, cocaine, and other illicit substances. This guidance has been developed to help health-care providers in identifying and managing smoking, alcohol, and substance use disorders in pregnant women and thereby reducing the risks of PTB and other adverse maternal and child health outcomes.

This guideline summarises information from the WHO, other guidance (where available), and recently conducted systematic reviews on the risks of and interventions for antenatal exposure to smoking, alcohol, and substance use for PTB.

2 Evidence Statement

Use of alcohol, tobacco, and other psychoactive substances during pregnancy leads to an increased risk of health problems for mother and child such as spontaneous abortion, stillbirth, low birth weight, birth defects, and prematurity (Table 1). Concurrent use of these substances (i.e. poly substance use) further increases the risk of adverse outcomes in all settings.

Table 1 Summary of evidenced tobacco, alcohol, and other substance use-related risk factors and interventions for PTB

This guideline proposes interventions (Table 1) for the identification and management of the following:

  1. (i)

    Tobacco smoking and exposure to second-hand smoke (SHS) (protection from SHS in homes and public places, screening, psychosocial, and pharmacological).

  2. (ii)

    Alcohol and illicit substance use (screening and dependency management) in pregnant women during the antenatal period.

Despite gaps in research and knowledge, the potential benefits of the recommended actions may help improve PTB and other birth outcomes.

3 Synopsis of the best Evidenced Risk Factors for Preterm Birth

For a summary of the evidence of tobacco, alcohol, and substance use-related risk factors for preterm birth, please see Table 1, in Sect. 5.

3.1 Smoking and Exposure to Second-Hand Smoke

  1. (i)

    A systematic review and meta-analysis (2000) of prospective studies for any maternal tobacco smoking versus no maternal smoking and preterm delivery found the pooled odds ratio to be 1.27 (95% CI 1.21–1.33, 20 studies, >100,000 participants) [1]. All the studies were conducted in high-income countries (HICs).

  2. (ii)

    A meta-analysis (2016) reported the ORs of PTB for women who were ever exposed to passive tobacco smoking versus women who had never been exposed to passive smoking at any place and at home were 1.20 (95% CI 1.07–1.34, 24 studies, 88,200 participants) and 1.16 (95% CI 1.04–1.30, 11 studies, 73,211 participants), respectively [2]. The associations were statistically significant for studies conducted in Asia (OR 1.26, 95% CI 1.05–1.52) [2]. Several studies were from low- and middle-income countries (LMICs) including China, India, Korea, and Indonesia.

  3. (iii)

    A systematic review and meta-analysis of observational studies in India also indicated that 0.19 million PTB (6% of all PTBs) could be attributed to the use smokeless tobacco (SLT) (pooled OR 1.39, 95% CI 1.01–1.91, 2 studies, 1800 participants) [3].

3.2 Alcohol Use

A dose-response relationship between alcohol consumption during pregnancy and the risks of PTB was observed in a meta-analysis (2011) of 14 observational studies (n = 280,443 pregnant women) primarily in HICs [4]. Compared with mothers who do not drink, the overall dose-response relationships for PTB showed (i) no effect up to 18 g pure alcohol or an average of 1.5 drinks/day and (ii) 23% increase in risk at an average of three drinks or 36 g/day (RR 1.23, 95% CI 1.05–1.44) [4].

3.3 Substance Use

  1. (i)

    Two systematic reviews (2016) were identified that explored maternal cannabis/marijuana use and the risks of preterm birth [5, 6]. No association was demonstrated between in utero exposure to marijuana/cannabis and PTB (pooled OR 1.29, 95% CI 0.80–2.08, 9 studies) compared to non-users [6]. Three studies included in the review showed an increase in odds of PTB, while six showed no association. Only two studies included were from LMICs—Iran and Jamaica [6]. Although marijuana use during pregnancy was associated with an increased risk of PTB in the pooled unadjusted analysis, (15.3% compared with 9.6%, pooled RR 1.32, 95% CI 1.14–1.54), results were found to be insignificant after adjusting for tobacco use and other confounding factors (pooled RR 1.08, 95% CI 0.82–1.43) [5].

  2. (ii)

    Opiate use (heroin, opium) is associated with an increased risk of premature birth and a number of other maternofoetal adverse outcomes. Findings from observational studies show that, compared to cocaine or opiate non-users, opiate users were 2.86 times as likely (95% Cl 1.11–7.36; p = 0.03) to deliver preterm [7]. Similar results were also seen in other observational studies conducted in Iran [8] and low-income, multi-ethnic US population [9].However research is heavily skewed to high-income country settings.

  3. (iii)

    Crack cocaine use during pregnancy was associated with significantly higher odds of preterm delivery (OR 2.22, 95% CI 1.59–3.10) [10]. Eight observational studies were included (n = 5761) in the meta-analysis; only one was from a LMIC (Iran) [10]. Systematic review and meta-analysis of 24 observational studies in HICs (n = 39,860) shows that cocaine use during pregnancy was associated with significantly higher odds of PTB (OR 3.38, 95% CI 2.72–4.21) [11].

  4. (iv)

    A significant increase in unadjusted risks of PTB (OR 4.11, 95% CI 3.05–5.55, 5 studies, n = 62,070) was identified among women exposed to amphetamines in pregnancy. All five studies included in the review were from HICs [12].

4 Practical Clinical Risk Assessment Instructions for PTB

4.1 Health-care providers should ask all pregnant women about their use of alcohol and other substances (past and present) early in pregnancy and at every antenatal visit. WHO recommends the use of validated screening instruments for this purpose [13, 14]. There may be cultural taboos which compound stigma and other difficulties in disclosure of substance use such as fear of judgement by health-care providers, breach of confidentiality, and fear of child removal after the birth.

4.2 All guidance encourages health-care practitioners to explore these issues sensitively, using a non-judgemental approach and in a confidential environment. There may, however, be child safeguarding issues which arise during this assessment which should be dealt with using in-country mechanisms, while optimising maternal physical and mental health. The presence of family members during maternal health checks may also act as a barrier to full disclosure.

4.3 Listed below are screening instruments that have been suggested to be used for prenatal assessment of pregnant women [13, 14]. There are variations in the tools regarding number of items, administration method (paper and pencil, computer), training needed, and location (prenatal clinic/outpatient/inpatient). Although some of the tools were validated, they will need to be further validated before use in an LMIC context.

  • Tobacco, alcohol, and substances: Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST Version 3.0); Pregnancy Information Program (PIP).

  • Alcohol and General Substance Use: 4P’s Plus [15]; Substance Use Risk Profile—Pregnancy (SURP-P) [16].

  • Alcohol: Alcohol Use Disorder Identification Test (AUDIT) [17]; Alcohol Use Disorder Identification Test—Consumption (AUDIT-C) [18]; CAGE [19]; Short Michigan Alcohol Screening Test (SMAST) [20]; Ten Question Drinking History (TQDH) [21]; T-ACE [22]; TWEAK [23].

5 Evidenced Effective Interventions for Risk Factors for Preterm Birth

These are summarised in Table 1.

6 Summary of Interventions for Smoking and Second-Hand Exposure to Smoke (Table 2)

Table 2 Benefits statements of effectiveness of smoking cessation interventions to prevent preterm birth

7 Summary of Interventions for Alcohol and Substance Use (Table 3)

Table 3 Benefits statements of effective interventions to promote harm reduction to prevent preterm birth

8 Research and Clinical Practice Recommendation

There is strong consensus within the literature about the negative effects of alcohol, tobacco, and substance use during pregnancy, and all women should receive necessary interventions to stop (preferably) or reduce use. The evidence is of low quality, and further primary research and controlled trials are needed on effective ways to assess exposure and the use of alcohol, tobacco (including second-hand exposure), and substances; measure the effect on maternal and child health outcomes and for determining the effectiveness and cost-effectiveness of recommended interventions in pregnancy. Additionally, there is also a dearth of studies conducted in LMICs. Assessment methods should include and integrate findings from policy, public health, behavioural and implementation science, and trials of interventions where PTB is the primary outcome measure. In addition, longitudinal cohort studies which include consideration of multi-factorial psychosocial factors are needed to assess the risks on women, children, and future generations.

References

  1. Shah NR, Bracken MB. A systematic review and meta-analysis of prospective studies on the association between maternal cigarette smoking and preterm delivery. Am J Obstet Gynecol. 2000;182(2):465–72.

    CAS  CrossRef  Google Scholar 

  2. Cui H, Gong TT, Liu CX, Wu QJ. Associations between passive maternal smoking during pregnancy and Preterm birth: evidence from a meta-analysis of observational studies. PLoS One. 2016;11(1):e0147848.

    CrossRef  Google Scholar 

  3. Suliankatchi RA, Sinha DN. The human cost of tobacco chewing among pregnant women in India: a systematic review and meta-analysis. J Obstet Gynaecol India. 2016;66(Suppl 1):161–6.

    CrossRef  Google Scholar 

  4. Patra J, Bakker R, Irving H, Jaddoe VW, Malini S, Rehm J. Dose-response relationship between alcohol consumption before and during pregnancy and the risks of low birthweight, preterm birth and small for gestational age (SGA)-a systematic review and meta-analyses. BJOG. 2011;118(12):1411–21.

    CAS  CrossRef  Google Scholar 

  5. Conner SN, Bedell V, Lipsey K, Macones GA, Cahill AG, Tuuli MG. Maternal marijuana use and adverse neonatal outcomes: a systematic review and meta-analysis. Obstet Gynecol. 2016;128(4):713–23.

    CrossRef  Google Scholar 

  6. Gunn JK, Rosales CB, Center KE, Nunez A, Gibson SJ, Christ C, et al. Prenatal exposure to cannabis and maternal and child health outcomes: a systematic review and meta-analysis. BMJ Open. 2016;6(4):e009986.

    CAS  CrossRef  Google Scholar 

  7. Quesada O, Gotman N, Howell HB, Funai EF, Rounsaville BJ, Yonkers KA. Prenatal hazardous substance use and adverse birth outcomes. J Matern Fetal Neona. 2012;25(8):1222–7.

    CrossRef  Google Scholar 

  8. Maghsoudlou S, Cnattingius S, Montgomery S, Aarabi M, Semnani S, Wikström A-K, et al. Opium use during pregnancy and infant size at birth: a cohort study. BMC Pregnancy Childbirth. 2018;18(1):358.

    CrossRef  Google Scholar 

  9. Azuine RE, Ji Y, Chang HY, Kim Y, Ji H, DiBari J, et al. Prenatal risk factors and perinatal and postnatal outcomes associated with maternal opioid exposure in an urban, low-income, multiethnic US population. JAMA Netw Open. 2019;2(6):e196405.

    CrossRef  Google Scholar 

  10. Dos Santos JF, de Melo Bastos Cavalcante C, Barbosa FT, DLG G, Duzzioni M, Tilelli CQ, et al. Maternal, fetal and neonatal consequences associated with the use of crack cocaine during the gestational period: a systematic review and meta-analysis. Arch Gynecol Obstet. 2018;298(3):487–503.

    CrossRef  Google Scholar 

  11. Gouin K, Murphy K, Shah PS, Knowledge Synthesis group on Determinants of Low Birth W, Preterm B. Effects of cocaine use during pregnancy on low birthweight and preterm birth: systematic review and meta-analysis. Am J Obstet Gynecol. 2011;204(4):340 e1–12.

    CrossRef  Google Scholar 

  12. Ladhani NN, Shah PS, Murphy KE. Knowledge synthesis group on determinants of Preterm LBWB. Prenatal amphetamine exposure and birth outcomes: a systematic review and metaanalysis. Am J Obstet Gynecol. 2011;205(3):219 e1–7.

    CrossRef  Google Scholar 

  13. WHO. Guidelines for the identification and Management of Substance use and Substance use Disorders in pregnancy by World Health Organization Geneva. Switzerland: WHO Press; 2014. ISBN: 9789241548731

    Google Scholar 

  14. WHO. WHO recommendations for the prevention and management of tobacco use and second-hand smoke exposure in pregnancy: World Health Organization; 2013.

    Google Scholar 

  15. Chasnoff IJ, Wells AM, McGourty RF, Bailey LK. Validation of the 4P's plus screen for substance use in pregnancy validation of the 4P's plus. J Perinatol. 2007;27(12):744–8.

    CAS  CrossRef  Google Scholar 

  16. Yonkers KA, Gotman N, Kershaw T, Forray A, Howell HB, Rounsaville BJ. Screening for prenatal substance use: development of the substance use risk profile-pregnancy scale. Obstet Gynecol. 2010;116(4):827–33.

    CrossRef  Google Scholar 

  17. Babor TF, Higgins-Biddle JC, Saunders JB, Monteiro MG. The alcohol use disorders identification test guidelines for use in primary care. WHO; 2001.

    Google Scholar 

  18. Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory care quality improvement project (ACQUIP). Alcohol use disorders identification test. Arch Intern Med. 1998;158(16):1789–95.

    CAS  CrossRef  Google Scholar 

  19. Ewing JA. Detecting alcoholism. The CAGE questionnaire Jama. 1984;252(14):1905–7.

    CAS  PubMed  Google Scholar 

  20. Powers JS, Spickard A. Michigan alcoholism screening test to diagnose early alcoholism in a general practice. South Med J. 1984;77(7):852–6.

    CAS  CrossRef  Google Scholar 

  21. Weiner L, Rosett HL, Edelin KC. Behavioral evaluation of fetal alcohol education for physicians. Alcohol Clin Exp Res. 1982;6(2):230–3.

    CAS  CrossRef  Google Scholar 

  22. Sokol RJ, Martier SS, Ager JW. The T-ACE questions: practical prenatal detection of risk-drinking. Am J Obstet Gynecol. 1989;160(4):863–8. discussion 8-70

    CAS  CrossRef  Google Scholar 

  23. Russell M, Bigler L. Screening for alcohol-related problems in an outpatient obstetric-gynecologic clinic. Am J Obstet Gynecol. 1979;134(1):4–12.

    CAS  CrossRef  Google Scholar 

  24. Gebara CFP, Bhona FMC, Ronzani TM, Lourenço LM, Noto AR. Brief intervention and decrease of alcohol consumption among women: a systematic review. Subst Abuse Treat Prev Policy. 2013;8(1):31.

    CrossRef  Google Scholar 

  25. Wright TE, Terplan M, Ondersma SJ, Boyce C, Yonkers K, Chang G, et al. The role of screening, brief intervention, and referral to treatment in the perinatal period. Am J Obstet Gynecol. 2016;215(5):539–47.

    CrossRef  Google Scholar 

  26. Gilinsky A, Swanson V, Power K. Interventions delivered during antenatal care to reduce alcohol consumption during pregnancy: a systematic review. Addict Res Theory. 2011;19(3):235–50.

    CrossRef  Google Scholar 

  27. Terplan M, Ramanadhan S, Locke A, Longinaker N, Lui S. Psychosocial interventions for pregnant women in outpatient illicit drug treatment programs compared to other interventions. Cochrane Database Syst Rev. 2015;4:CD006037.

    Google Scholar 

  28. Wang MJ, Kuper SG, Sims B, Paddock CS, Dantzler J, Muir S, et al. Opioid detoxification in pregnancy: systematic review and meta-analysis of perinatal outcomes. Am J Perinatol. 2019;36(6):581–7.

    CrossRef  Google Scholar 

  29. Dashe JS, Nelson DB, Stewart RD, Adhikari EH, Roberts SW, Wendel GD Jr. Opioid detoxification during pregnancy: a systematic review. Obstet Gynecol. 2018;132(4):1061.

    CrossRef  Google Scholar 

  30. Minozzi S, Amato L, Bellisario C, Ferri M, Davoli M. Maintenance agonist treatments for opiate-dependent pregnant women. Cochrane Database Syst Rev. 2013;12:CD006318.

    Google Scholar 

  31. Terplan M, Laird HJ, Hand DJ, Wright TE, Premkumar A, Martin CE, et al. Opioid detoxification during pregnancy: a systematic review. Obstet Gynecol. 2018;131(5):803–14.

    CrossRef  Google Scholar 

  32. Chamberlain C, O'Mara-Eves A, Oliver S, Caird JR, Perlen SM, Eades SJ, et al. Psychosocial interventions for supporting women to stop smoking in pregnancy. Cochrane Database Syst Rev. 2013;10:CD001055.

    Google Scholar 

  33. Lumley J, Chamberlain C, Dowswell T, Oliver S, Oakley L, Watson L. Interventions for promoting smoking cessation during pregnancy. Cochrane Database Syst Rev. 2009;3:CD001055.

    Google Scholar 

  34. Chamberlain C, O'Mara-Eves A, Porter J, Coleman T, Perlen SM, Thomas J, et al. Psychosocial interventions for supporting women to stop smoking in pregnancy. Cochrane Database Syst Rev. 2017;2:CD001055.

    PubMed  Google Scholar 

  35. Claire R, Chamberlain C, Davey MA, Cooper SE, Berlin I, Leonardi-Bee J, et al. Pharmacological interventions for promoting smoking cessation during pregnancy. Cochrane Database Syst Rev. 2020;3:CD010078.

    PubMed  Google Scholar 

  36. Faber T, Kumar A, Mackenbach JP, Millett C, Basu S, Sheikh A, et al. Effect of tobacco control policies on perinatal and child health: a systematic review and meta-analysis. Lancet Public Health. 2017;2(9):e420–e37.

    CrossRef  Google Scholar 

  37. Been JV, Nurmatov UB, Cox B, Nawrot TS, van Schayck CP, Sheikh A. Effect of smoke-free legislation on perinatal and child health: a systematic review and meta-analysis. Eur J Paediatr Dent. 2015;16(3):210–1.

    PubMed  Google Scholar 

  38. Zhang L, Hsia J, Tu X, Xia Y, Zhang L, Bi Z, et al. Exposure to secondhand tobacco smoke and interventions among pregnant women in China: a systematic review. Prev Chronic Dis. 2015;12:E35.

    PubMed  PubMed Central  Google Scholar 

  39. Dherani M, Zehra SN, Jackson C, Satyanaryana V, Huque R, Chandra P, et al. Behaviour change interventions to reduce second-hand smoke exposure at home in pregnant women - a systematic review and intervention appraisal. BMC Pregnancy Childbirth. 2017;17(1):378.

    CrossRef  Google Scholar 

  40. Tong VT, Dietz PM, Rolle IV, Kennedy SM, Thomas W, England LJ. Clinical interventions to reduce secondhand smoke exposure among pregnant women: a systematic review. Tob Control. 2015;24(3):217–23.

    CrossRef  Google Scholar 

  41. Nwosu C, Angus K, Cheeseman H, Semple S. Reducing second-hand smoke exposure among non-smoking pregnant women: a systematic review. Nicotine & tobacco research: official journal of the Society for Research on Nicotine and Tobacco. 2020.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Shumona Sharmin Salam .

Editor information

Editors and Affiliations

Rights and permissions

Open Access This chapter is licensed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

The images or other third party material in this chapter are included in the chapter's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the chapter's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

Reprints and Permissions

Copyright information

© 2022 The Author(s)

About this chapter

Verify currency and authenticity via CrossMark

Cite this chapter

Salam, S.S., Mitchell, C. (2022). Evaluating Alcohol, Tobacco, and Other Substance Use in Pregnant Women. In: Anumba, D.O., Jayasooriya, S.M. (eds) Evidence Based Global Health Manual for Preterm Birth Risk Assessment . Springer, Cham. https://doi.org/10.1007/978-3-031-04462-5_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-04462-5_7

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-04461-8

  • Online ISBN: 978-3-031-04462-5

  • eBook Packages: MedicineMedicine (R0)